HYPOFRACTIONATED RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME
Purpose: The purpose of this study was to assess the outcomes in glioblastoma patients treated with hypofractionated radiotherapy. Materials and Methods: We reviewed all glioblastoma patients treated at our specialist cancer centre over 7 and a 1⁄2 years using hypofractionated radiotherapy (HRT) p...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Shaukat Khanum Memorial Trust
2015-11-01
|
Series: | Journal of Cancer and Allied Specialties |
Online Access: | http://journals.sfu.ca/jcas/index.php/jcas/article/view/31 |
id |
doaj-43e2dc3483a741faaff2a82f69e1ce41 |
---|---|
record_format |
Article |
spelling |
doaj-43e2dc3483a741faaff2a82f69e1ce412021-10-02T18:24:30ZengShaukat Khanum Memorial TrustJournal of Cancer and Allied Specialties2411-989X2015-11-011210.37029/jcas.v1i2.31HYPOFRACTIONATED RADIOTHERAPY IN GLIOBLASTOMA MULTIFORMESadaf Usman0Samreen J Chaudry1Shahid HameedKamran Hussain2Sumera Butt3Radiation oncology dept. SKMCH&RC, LahoreRadiation Oncology department, SKMCH&RC, LahoreSurgical Oncology, SKMCH&RC, LahoreRadiation Oncology, SKMCH&RC, Lahore Purpose: The purpose of this study was to assess the outcomes in glioblastoma patients treated with hypofractionated radiotherapy. Materials and Methods: We reviewed all glioblastoma patients treated at our specialist cancer centre over 7 and a 1⁄2 years using hypofractionated radiotherapy (HRT) postoperatively. The HRT regimen was 48 Gy given at 3 Gy/ fractions in 16 fractions. We calculated overall survival using time to event analyses. Results: A total of 62 patients were identi ed of whom 44 (71%) were male. The median age of these patients was 50 years (range: 20–71 years). Eastern Cooperative Oncology Group (ECOG) performance status was 0 in 47 (76%) and 1 in 15 (24%) patients. 7 (11%) of the patients underwent gross total resection, 52 (83%) had subtotal resection and 3 (5%) had a biopsy only. Response assessment on magnetic resonance imaging at 3-month post-HRT showed that 14 (22%) patients had regression, 21 (34%) were stable and 22 (35%) had a progressive primary tumour. 5 (8%) patients were lost to follow up. With a median follow-up of 7.8 months, the median overall survival was 9 months. Patients with ECOG-0 showed a median survival of 7 months as compared to 6 months for those with ECOG-1. Patients with stable or partial response showed a median overall survival of 8 months in comparison to 6 months for those with progressive disease. There were no signi cant differences in median survival based on the extent of surgery. A Cox multivariate model con rmed signi cant correlation of age and response to radiotherapy with survival. Conclusion: HRT consisting of 48 Gy in 3 weeks can be used for selected glioblastoma patients to reduce the overall treatment time of conventional radiotherapy by 35–40% without apparent increased toxicity or decrement in survival in a low resource environment. Key words: Chemoradiation, glioblastoma, hypofractionated radiotherapy, survival http://journals.sfu.ca/jcas/index.php/jcas/article/view/31 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Sadaf Usman Samreen J Chaudry Shahid Hameed Kamran Hussain Sumera Butt |
spellingShingle |
Sadaf Usman Samreen J Chaudry Shahid Hameed Kamran Hussain Sumera Butt HYPOFRACTIONATED RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME Journal of Cancer and Allied Specialties |
author_facet |
Sadaf Usman Samreen J Chaudry Shahid Hameed Kamran Hussain Sumera Butt |
author_sort |
Sadaf Usman |
title |
HYPOFRACTIONATED RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME |
title_short |
HYPOFRACTIONATED RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME |
title_full |
HYPOFRACTIONATED RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME |
title_fullStr |
HYPOFRACTIONATED RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME |
title_full_unstemmed |
HYPOFRACTIONATED RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME |
title_sort |
hypofractionated radiotherapy in glioblastoma multiforme |
publisher |
Shaukat Khanum Memorial Trust |
series |
Journal of Cancer and Allied Specialties |
issn |
2411-989X |
publishDate |
2015-11-01 |
description |
Purpose: The purpose of this study was to assess the outcomes in glioblastoma patients treated with hypofractionated radiotherapy.
Materials and Methods: We reviewed all glioblastoma patients treated at our specialist cancer centre over 7 and a 1⁄2 years using hypofractionated radiotherapy (HRT) postoperatively. The HRT regimen was 48 Gy given at 3 Gy/ fractions in 16 fractions. We calculated overall survival using time to event analyses.
Results: A total of 62 patients were identi ed of whom 44 (71%) were male. The median age of these patients was 50 years (range: 20–71 years). Eastern Cooperative Oncology Group (ECOG) performance status was 0 in 47 (76%) and 1 in 15 (24%) patients. 7 (11%) of the patients underwent gross total resection, 52 (83%) had subtotal resection and 3 (5%) had a biopsy only. Response assessment on magnetic resonance imaging at 3-month post-HRT showed that 14 (22%) patients had regression, 21 (34%) were stable and 22 (35%) had a progressive primary tumour. 5 (8%) patients were lost to follow up. With a median follow-up of 7.8 months, the median overall survival was 9 months. Patients with ECOG-0 showed a median survival of 7 months as compared to 6 months for those with ECOG-1. Patients with stable or partial response showed a median overall survival of 8 months in comparison to 6 months for those with progressive disease. There were no signi cant differences in median survival based on the extent of surgery. A Cox multivariate model con rmed signi cant correlation of age and response to radiotherapy with survival.
Conclusion: HRT consisting of 48 Gy in 3 weeks can be used for selected glioblastoma patients to reduce the overall treatment time of conventional radiotherapy by 35–40% without apparent increased toxicity or decrement in survival in a low resource environment.
Key words: Chemoradiation, glioblastoma, hypofractionated radiotherapy, survival
|
url |
http://journals.sfu.ca/jcas/index.php/jcas/article/view/31 |
work_keys_str_mv |
AT sadafusman hypofractionatedradiotherapyinglioblastomamultiforme AT samreenjchaudry hypofractionatedradiotherapyinglioblastomamultiforme AT shahidhameed hypofractionatedradiotherapyinglioblastomamultiforme AT kamranhussain hypofractionatedradiotherapyinglioblastomamultiforme AT sumerabutt hypofractionatedradiotherapyinglioblastomamultiforme |
_version_ |
1716849166359986176 |